Modality
mRNA
MOA
CAR-T CD19
Target
Nectin-4
Pathway
Notch
Wet AMDFL
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Jan 2028
Phase 2Current
NCT04592983
277 pts·Wet AMD
2018-07→2028-01·Terminated
277 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-111.8y awayPh2 Data· Wet AMD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2
Termina…
Catalysts
Ph2 Data
2028-01-11 · 1.8y away
Wet AMD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04592983 | Phase 2 | Wet AMD | Terminated | 277 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 |